A RESOLUTION recognizing May 2026 as Amyotrophic Lateral Sclerosis Awareness Month in Kentucky.
SR187 is a simple Senate resolution recognizing May 2026 as Amyotrophic Lateral Sclerosis (ALS) Awareness Month in Kentucky. The resolution describes ALS, also known as Lou Gehrig’s disease, as a progressive and fatal neurodegenerative disease that affects a person’s ability to walk, talk, eat, and breathe, and notes that there is currently no known cure. It also highlights the urgency of the disease by citing the frequency of diagnosis and death, the typical survival window after diagnosis, and the importance of research, clinical trials, assistive technologies, and access to durable medical equipment and communication devices.
The resolution further emphasizes the connection between military service and a higher likelihood of developing ALS, and it praises the ALS Association for its research funding and broader efforts to accelerate discovery. Rather than changing substantive law, the measure is commemorative and educational, intended to raise public awareness and acknowledge ongoing research and the challenges faced by people living with ALS. It directs the Senate Clerk to transmit a copy to Senator Steve Rawlings.
SR187 does not amend, create, or repeal any Kentucky statutes. Its legal effect is limited to an official legislative recognition of ALS Awareness Month and a ceremonial transmission of the resolution. The practical impact is symbolic: it may help elevate public awareness, encourage support for ALS research and services, and draw attention to affected patients, caregivers, veterans, and organizations involved in treatment and advocacy.
The available context indicates broad support and a noncontroversial tone. The resolution was adopted by voice vote, which typically reflects consensus and little or no recorded opposition. The bill text itself is framed in strongly sympathetic terms, emphasizing the severity of ALS, the lack of a cure, and the need for research and support services, all of which suggest a favorable sentiment toward the measure.
No substantive contention is evident in the bill text or voting history provided. Because the resolution is honorary and awareness-focused, there are no apparent disputes over policy changes, funding, or regulatory effects. The only notable policy-related emphasis is on the importance of research, clinical trials, and access to therapies and equipment, but these are presented as supportive findings rather than contested provisions.